THE BIOCHEMICAL MARKERS OF NEUROENDOCRINE TUMORS: ANALYTICAL AND CLINICAL ASPECTS

DOI: https://doi.org/None

N.V. Lyubimova Moscow State University of Medicine and Dentistry т amed after A.I. Evdokimov, Delegatskaya Str., 20, Moscow, Russian Federation, 127473

The lecture considers common concepts of neuroendocrine tumors (NETs). Unlike the other tumors, NETs synthesize a variety of biologically active substances (hormones, peptides, amines), that being their main feature with multiple consequences leads to the development of distinct clinical presentations. The most important biochemical markers of NETs are characterized, with a description of the analytical aspects of their investigation as well as various endogenous and exogenous factors influencing on the results. The clinical value of general and specific markers and algorithm for their use in different types of NETs are presented. Data on diagnostic sensitivity of chromogranin A (CgA), as the most significant marker of NETs with recommendations for its use in diagnostics, monitoring, assessment of distribution and prognosis of tumors with neuroendocrine nature are submitted. Highly effective determination of CgA and pancreatic polypeptide in diagnostics of nonfunctioning NETs of the pancreas is presented. The importance of complex assays of CgA with specific markers (serotonin and/or its metabolite 5-HIAA) for identification and monitoring of carcinoid syndrome is shown.
Keywords: 
neuroendocrine tumors, biochemical markers, diagnostics
Список литературы: 
  1. Barter R., Pearse A.G. Mammalian enterochromaffin cells as the source of serotonin (5-hydroxytryptamin). J. Pathol. Bacteriol. 1955; 69 (1–2): 25–31.
  2. Caplin M.E., Buscombe J.R., Hilson A.J. et al. Carcinoid tumour. Lancet. 1998; 352 (9130): 799–805.
  3. Modlin I.M., Latich I., Zikusoka M. et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J. Clin. Gastroenterol. 2006; 40 (7): 572–82.
  4. Aunis D., Metz-Boutigue M.H. Chromogranins: current concepts. Structural and functional aspects. Adv. Exp. Med. Biol. 2000; 482: 21–38.
  5. Feldman S.A., Eiden L.E. The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr. Pathol. 2003. Spring; 14 (1): 3–23.
  6. Louthan O. ChromograninA in physiology and oncology. Folia Biol (Praha). 2011; 57 (5): 173–81.
  7. Modlin I.M., Gustafsson B.I., Moss S.F. et al. Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease. Ann. Surg. Oncol. 2010; 17 (9): 2427–43.
  8. Ardill J.E. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Ann. Clin. Biochem. 2008; 45 (6): 539–59.
  9. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer. 2011; 18 (Suppl 1): 17–25.
  10. O’Toole D., Grossman A., Gross D. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology. 2009; 90 (2): 194–202.
  11. Vinik A.I., Silva M.P., Woltering E.A. et al. Biochemical testing for neuroendocrine tumors. Pancreas. 2009; 38 (8): 876–89.
  12. Nikou G.C., Marinou K., Thomakos P. et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology. 2008; 8 (4-5): 510–19.
  13. Campana D., Nori F., Piscitelli L. et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J. Clin. Oncol. 2007; 25 (15): 1967–73.
  14. Panzuto F., Severi C., Cannizzaro R. et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J. Endocrinol. Invest. 2004; 27 (1): 6–11.
  15. Walter T., Chardon L., Chopin-laly X. et al. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours? Eur. J. Cancer. 2012; 48 (12): 1766–73.
  16. Lesurtel M., Soll C., Graf R., Clavien P.A. Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives. Cell. Mol. Life Sci. 2008; 65 (6): 940–52.
  17. Ramage J.K., Davies A.H., Ardill J. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005; 54 (Suppl. 4): 1–16.
  18. Zuetenhorst J.M., Korse C.M., Bonfrer J.M. et al. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors. Clin. Chem. 2004; 50 (9): 1634–39.